Product name | Eptifibatide acetate |
Sequence | Mpr-Har-Gly-Asp-Trp-Pro-Cys-NH2 |
CAS No. | 188627-80-7 (Eptifibatide (net)), 148031-34-9 (Eptifibatide acetate) |
Molecular Formula | C35H49N11O9S2 |
Molecular Weight | 832.4 |
Molecule Structure |  |
Quality Standard | 98% up by HPLC, GMP |
Appearance | White slightly yellwish powder |
COA of Eptifibatide acetate |
Items | Specification | Results |
Appearance | White slightly yellwish powder | Conforms |
Purity(HPLC) | > 98% | 99.57% |
Peptide | ≥ 80% |
|
Amino acids | Asp:0.85-1.15 Cys:0.75-1.15 Gly:0.85-1.15 Pro: 0.85-1.15 Har: 0.85-1.15 Trp:Present | 1.08 1.00 0.98 1,06 1.07 |
Specific optical rotation | -53- -57°(C=5, 1% Acetic acid) | -55.6° |
Solubility | Soluble in water and 1% acetic acid at a concentration of ≥ 1mg/ml to give a clear, colorless solution | Conforms |
Related substances (HPLC) | Total impurities: ≤ 1.5%
Any impurity: ≤ 1.0% | 0.6% 0.2% |
Water (Karl Fischer) | ≤ 5.0 % | 3.8% |
Acetic acid (HPLC) | ≤ 10.0% | 8.7% |
Bacterial endotoxins | < 10EU/mg | Conforms |
Mass balance | 95.0%-105.% | 98.11% |
DMF (GC) | ≤0.088% | Conforms |
can | ≤0.041% | Conforms |
Conclusion | Complies with the standard. |
Function of Eptifibatide acetate
Eptifibatide acetate is a cyclic heptapeptide, a glycoprotein IIb/IIIa receptor inhibitor, and has antiplatelet activity.
Application of Eptifibatide acetate
Eptifibatide acetate is used for the treatment of acute coronary syndrome (unstable angina pectoris/non-ST-elevation myocardial infarction), including patients who will receive medical treatment or who are planning to undergo percutaneous coronary intervention (PCI).
